Am J Transplant, Volume 21, Suppl 3 Archives - Page 46 of 139 - ATC Abstracts

2021 American Transplant Congress
Donor-derived Cell-free DNA Distinguishes Acute Rejection from Other Causes of Graft Injury in Liver Transplant Recipients
J. Levitsky¹, M. Miller², R. Sinha², E. Bixler², A. Al-Turck², J. Weems², M. Altrich², S. Kleiboeker², M. Abecassis³
¹Gastroenterology & Hepatology; Comprehensive Transplant Center, Northwestern University, Chicago, IL, ²Viracor Eurofins, Lees Summit, MO, ³University of Arizona College of Medicine Tucson, Tucson, AZ
*Purpose: The donor derived cell-free DNA (ddcfDNA) has emerged as strong biomarker for allograft injury, where the fraction of ddcfDNA is reported to increase in…
2021 American Transplant Congress
Association Between HLA Class II and TLR4 Regulates HLA-II Stimulated P-selectin Expression and Monocyte Capture to Endothelial Cells
Y. Jin, J. Nevarez-Mejia, E. F. Reed
Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA
*Purpose: Antibody-mediated rejection (AMR) is a major obstacle for long-term allograft survival. Donor specific HLA antibodies (DSA) contribute to the process of AMR by binding…
2021 American Transplant Congress
Epidemiology and Risk Factors for Invasive Fungal Infection in Pancreas Transplant in the Absence of Fungal Prophylaxis
J. Burkey¹, J. M. Chen², A. A. Sharfuddin², M. S. Yaqub², A. J. Lutz², J. A. Powelson², J. A. Fridell², N. Barros²
¹Butler University College of Pharmacy and Health Sciences, Indianapolis, IN, ²Indiana University Health, Indianapolis, IN
*Purpose: Invasive fungal infections (IFI) remain a rare yet dreaded complication following pancreas transplantation. Current guidelines recommend antifungal prophylaxis in patients with 1 or more…
2021 American Transplant Congress
Outcomes After Liver Transplantation With Steatotic Grafts: Redefining Acceptable Cutoffs for Moderately Steatotic Grafts
B. L. Da¹, J. Satiya², R. P. Heda³, Y. Jiang⁴, L. Lau⁵, A. Fahmy¹, A. Winnick¹, N. Roth¹, E. Grodstein¹, P. J. Thuluvath⁶, A. K. Singal⁷, T. D. Schiano⁸, L. W. Teperman¹, S. K. Satapathy¹
¹Liver Disease, Northwell Health, Manhasset, NY, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Tulane Medical Center, Memphis, TN, ⁴The University of Memphis, Memphis, TN, ⁵Northwell Health, Manhasset, NY, ⁶University of Maryland School of Medicine, Baltimore, MD, ⁷Liver Disease, Avera McKenna University Health Center and Transplant Institute, Manhasset, NY, ⁸Icahn School of Medicine at Mount Sinai, New York City, NY
*Purpose: Graft macro-steatosis can predispose to worse graft survival. Our objective was to redefine acceptable cutoffs for graft steatosis using the national database.*Methods: Data of…
2021 American Transplant Congress
PD-1/PD-L1 Selectively Regulates Treg Lymphatic Migration
W. Piao¹, L. Li¹, C. Paluskievicz¹, Y. Zhang², V. Saxena³, K. Hippen², B. Blazar², L. Riella⁴, J. Bromberg¹
¹Surgery, U Maryland, Baltimore, MD, ²U Minnesota, Minneapolis, MN, ³U Maryland, Baltimore, MD, ⁴Harvard U, Boston, MA
*Purpose: The molecules that regulate Treg migration are incompletely identified. Programmed death-1 (PD-1) and its ligand PD-L1 are immune checkpoint proteins which regulate immune cell…
2021 American Transplant Congress
Efficacy of MAU868, a Novel BKV Neutralizing Monoclonal Antibody (mAb), for the Treatment of Severe BK Virus Nephropathy (BKVN) After Kidney Transplant
S. C. Jordan¹, N. Ammerman², M. Toyoda³, K. Lim², J. R. Abend⁴, A. Patick⁵, M. R. Hodges⁵, A. Vo², S. J. Kovacs⁶
¹Comprehensive Transplant Center, Cedars Sinai Medical Ctr, West Hollywood, CA, ²Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA, ³Cedars Sinai Medical Ctr, Los Angeles, CA, ⁴Novartis Institutes for BioMedical Research, Virology Research, Emeryville, CA, ⁵Amplyx Pharmaceuticals, San Diego, CA, ⁶Novartis Institutes for BioMedical Research, Translational Medicine, East Hanover, NJ
*Purpose: BKV reactivation leading to nephropathy and allograft loss in kidney transplant (KT) recipients remains a clinical significant concern. No specific or effective anti-BKV therapies…
2021 American Transplant Congress
Disparities in Access to Listing in Rural Populations Post-KAS Implementation
S. H. Nguyen¹, R. R. Redfield², N. Neidlinger¹, D. P. Foley¹, D. B. Kaufman¹, J. T. Adler³
¹Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Department of Surgery, University of Pennsylvania, Philadelphia, PA, ³Department of Surgery, Brigham and Women’s Hospital, Boston, MA
*Purpose: One major goal of the Kidney Allocation System (KAS) was to improve access to transplantation. The impact of KAS on rural populations has been…
2021 American Transplant Congress
Impaired Antibody Responses to Spike Protein Antigens of Sars-cov-2 in Solid Organ Transplant (sot) Recipients
C. Ashokkumar¹, S. Nadig², V. Rohan², A. Kroemer³, H. Dhani³, S. Rao⁴, R. Sindhi⁵
¹Plexision, pittsburgh, PA, ²Medical University of South Carolina, Charleston, SC, ³MedStar Georgetown Transplant Institute, Georgetown, DC, ⁴DHR Health Institute for Research and Development, Texas, TX, ⁵University of Pittsburgh, Pittsburgh, PA
*Purpose: Chronic immunosuppression can impair antibody responses after natural infection and vaccination in SOT recipients. It is not known whether antibody responses are impaired in…
2021 American Transplant Congress
Investigating the HLA Alloimmune Background of the Histological Changes Suggestive of Antibody-mediated Injury in the Absence of Donor-specific Anti-HLA Antibodies
A. Senev, M. Naesens
Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
*Purpose: The histology of antibody-mediated rejection is observed frequently after kidney transplantation, but a significant percentage of the patients do not have detectable donor-specific HLA…
2021 American Transplant Congress
The Gut Microbiotainduces Local and Systemic Immune Modulation
V. Saxena, R. Lakhan, J. Iyyathurai, W. Piao, L. Li, T. Zhang, M. W. Shirkey, B. Ma, E. F. Mongodin, J. Bromberg
U Maryland, Baltimore, MD
*Purpose: We previously demonstrated that gut microbiome alterations, through fecal microbiota transfer (FMT) or single bacteria transfer, had specific immune effects for cardiac allograft outcome.…